122 related articles for article (PubMed ID: 19683985)
1. Immunoreactivity for alpha-smooth muscle actin characterizes a potentially aggressive subgroup of little basal cell carcinomas.
Pilloni L; Bianco P; Manieli C; Senes G; Coni P; Atzori L; Aste N; Faa G
Eur J Histochem; 2009; 53(2):113-6. PubMed ID: 19683985
[TBL] [Abstract][Full Text] [Related]
2. Immunoreactivity for alpha-smooth muscle actin characterizes a potentially aggressive subgroup of little basal cell carcinomas.
Pilloni L; Bianco P; Manieli C; Senes G; Coni P; Atzori L; Aste N; Faa G
Eur J Histochem; 2009 Jun; 53(2):e14. PubMed ID: 30256877
[TBL] [Abstract][Full Text] [Related]
3. Microcystic adnexal carcinoma: an immunohistochemical study including markers of proliferation and apoptosis.
Smith KJ; Williams J; Corbett D; Skelton H
Am J Surg Pathol; 2001 Apr; 25(4):464-71. PubMed ID: 11257620
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical evaluation of basal cell carcinoma and trichepithelioma using Bcl-2, Ki67, PCNA and P53.
Abdelsayed RA; Guijarro-Rojas M; Ibrahim NA; Sangueza OP
J Cutan Pathol; 2000 Apr; 27(4):169-75. PubMed ID: 10774937
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical nuclear staining for p53, PCNA, Ki-67 and bcl-2 in different histologic variants of basal cell carcinoma.
Mateoiu C; Pirici A; Bogdan F
Rom J Morphol Embryol; 2011; 52(1 Suppl):315-9. PubMed ID: 21424069
[TBL] [Abstract][Full Text] [Related]
6. Expression of p53, D2-40 and α-smooth muscle actin in different histological subtypes of facial basal cell carcinoma.
Mercut R; Ciurea ME; Mărgăritescu C; Popescu SM; Crăitoiu MM; Cotoi OS; Voinescu DC
Rom J Morphol Embryol; 2014; 55(2):263-72. PubMed ID: 24969973
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical expression of p53, Ki67, α-SMA, CD44 and CD31 in different histological subtypes of basal cell carcinoma.
Cojocaru A; Bîrjovanu C; Ciurea AM; Niculescu D; Orzan OA; Ion A; Alexandru DO; Pirici I; Vîlcea EJ; Marinescu EA; Ciurea ME
Rom J Morphol Embryol; 2022; 63(2):383-393. PubMed ID: 36374143
[TBL] [Abstract][Full Text] [Related]
8. Stromal expression of actin is a marker of aggressiveness in basal cell carcinoma.
Adegboyega PA; Rodriguez S; McLarty J
Hum Pathol; 2010 Aug; 41(8):1128-37. PubMed ID: 20381122
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis.
Vidal D; Matías-Guiu X; Alomar A
Br J Dermatol; 2004 Sep; 151(3):656-62. PubMed ID: 15377354
[TBL] [Abstract][Full Text] [Related]
10. A correlation of alpha-smooth muscle actin and invasion in micronodular basal cell carcinoma.
Christian MM; Moy RL; Wagner RF; Yen-Moore A
Dermatol Surg; 2001 May; 27(5):441-5. PubMed ID: 11359490
[TBL] [Abstract][Full Text] [Related]
11. Bcl-2-related proteins, alpha-smooth muscle actin and amyloid deposits in aggressive and non-aggressive basal cell carcinomas.
Bozdogan O; Erkek E; Atasoy P; Koçak M; Birol A; Caydere M
Acta Derm Venereol; 2002; 82(6):423-7. PubMed ID: 12575847
[TBL] [Abstract][Full Text] [Related]
12. Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2.
Zagrodnik B; Kempf W; Seifert B; Müller B; Burg G; Urosevic M; Dummer R
Cancer; 2003 Dec; 98(12):2708-14. PubMed ID: 14669293
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical nuclear staining for p53, PCNA, and Ki-67 in different histologic variants of basal cell carcinoma.
Barrett TL; Smith KJ; Hodge JJ; Butler R; Hall FW; Skelton HG
J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):430-7. PubMed ID: 9308559
[TBL] [Abstract][Full Text] [Related]
14. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates.
Nakopoulou L; Vourlakou C; Zervas A; Tzonou A; Gakiopoulou H; Dimopoulos MA
Hum Pathol; 1998 Feb; 29(2):146-54. PubMed ID: 9490274
[TBL] [Abstract][Full Text] [Related]
15. A Comparative Study of CD56 and Smooth Muscle Actin Expression in Basal and Squamous Cell Carcinomas.
Yirmibes S; Balaban Adim S
Am J Dermatopathol; 2023 Dec; 45(12):816-819. PubMed ID: 37982465
[TBL] [Abstract][Full Text] [Related]
16. bcl-2 protein expression in aggressive and non-aggressive basal cell carcinomas.
Ramdial PK; Madaree A; Reddy R; Chetty R
J Cutan Pathol; 2000 Jul; 27(6):283-91. PubMed ID: 10885404
[TBL] [Abstract][Full Text] [Related]
17. Actin expression in purely nodular versus nodular-infiltrative basal cell carcinoma.
Law AM; Oliveri CV; Pacheco-Quinto X; Horenstein MG
J Cutan Pathol; 2003 Apr; 30(4):232-6. PubMed ID: 12680952
[TBL] [Abstract][Full Text] [Related]
18. Metastatic basal cell carcinoma: four case reports, review of literature, and immunohistochemical evaluation.
Ionescu DN; Arida M; Jukic DM
Arch Pathol Lab Med; 2006 Jan; 130(1):45-51. PubMed ID: 16390237
[TBL] [Abstract][Full Text] [Related]
19. Interaction between bcl-2 and P53 in neoplastic progression of basal cell carcinoma of the head and neck.
Staibano S; Lo Muzio L; Pannone G; Scalvenzi M; Salvatore G; Errico ME; Fanali S; De Rosa G; Piattelli A
Anticancer Res; 2001; 21(6A):3757-64. PubMed ID: 11911244
[TBL] [Abstract][Full Text] [Related]
20. [Immunomorphological features of cutaneous basal-cell carcinoma].
Chuprov IN
Vopr Onkol; 2008; 54(6):715-9. PubMed ID: 19241845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
